\square

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Check this box if no longer subject to
Section 16. Form 4 or Form 5
obligations may continue. See
Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL OMB Number: 3235-0287

Estimated average burden	
hours per response:	0.5

1 Indiric and Address of Reporting Ferson		son [*]	2. Issuer Name and Ticker or Trading Symbol bluebird bio, Inc. [BLUE]	5. Relationship of Reporting Person(s) to Issuer (Check all applicable)						
				X	Director	Х	10% Owner			
	(First) OCK VENTURES		3. Date of Earliest Transaction (Month/Day/Year) 09/11/2014		Officer (give title below)	Other (specify below)				
29 NEWBURY STREET, 3RD FLOOR		4LOOR	4. If Amendment, Date of Original Filed (Month/Day/Year)	6. Indiv Line)	vidual or Joint/Group Filing (Check Applicable					
(Street)				X	Form filed by One	Repor	ting Person			
BOSTON	MA	02116			Form filed by Mo Person	e than (One Reporting			
(City)	(State)	(Zip)								

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

Table 1 - Non Bernarive Geodinices Adquired, Disposed of, or Beneficially Owned											
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)					5. Amount of Securities Beneficially Owned Following	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership	
			Code	v	Amount	(A) or (D)	Price	Reported Transaction(s) (Instr. 3 and 4)		(Instr. 4)	
Common Stock	09/11/2014		S		87,000	D	\$36.52(1)	2,329,974	Ι	See footnote ⁽²⁾	
Common Stock	09/11/2014		J ⁽³⁾		1,076,920	D	\$0	1,253,054	I	See footnote ⁽²⁾	
Common Stock	09/11/2014		J ⁽⁴⁾		79,062	A	\$0	79,062	Ι	See footnote ⁽⁵⁾	
Common Stock	09/11/2014		J ⁽⁶⁾		79,062	D	\$0	0	I	See footnote ⁽⁵⁾	
Common Stock	09/11/2014		J ⁽⁷⁾		11,449	A	\$0	26,538	D		
Common Stock	09/12/2014		s		38,000	D	\$36.59(8)	1,215,054	Ι	See footnote ⁽²⁾	

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transa Code (8)		5. Nu of Deriv Secu Acqu (A) or Dispo of (D) (Instr and 5	ative rities ired osed	6. Date Exerc Expiration Da (Month/Day/Y	ate	7. Title Amouri Securi Underi Deriva Securi and 4)	nt of ties ying tive ty (Instr. 3	8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares				

Explanation of Responses:

1. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$36.00 to \$36.95, inclusive. The Reporting Person undertakes to provide to bluebird bio Inc., any security holder of bluebird bio Inc., or the staff of the Securities and Exchange Commission (the "SEC"), upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

2. The shares are directly held by Third Rock Ventures, L.P. ("TRV"). The general partner of TRV is Third Rock Ventures GP, L.P. ("TRV GP"). The general partner of TRV GP LLC") and, as such, each of TRV GP and TRV GP LLC exercises shared voting and investment power over the shares held of record by TRV. As a manager of TRV GP LLC, the Reporting Person disclaims beneficial ownership of the shares except to the extent of his pecuniary interest therein, if any.

3. Distribution of shares in kind by TRV on a pro rata basis to its partners.

4. TRV GP received shares distributed in kind by TRV on a pro rata basis to its partners.

5. The shares are directly held by TRV GP. As such, TRV GP LLC and the Reporting Person, exercises voting and investment power over the shares held of record by TRV GP. The Reporting Person disclaims beneficial ownership of the shares except to the extent of his pecuniary interest therein, if any.

6. Distribution of shares in kind by TRV GP on a pro rata basis to its partners.

7. The Reporting Person received shares distributed in kind by TRV GP on a pro rata basis to its partners.

8. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$36.25 to \$37.005, inclusive. Each Reporting Person undertakes to provide to bluebird bio Inc., any security holder of bluebird bio Inc., or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote

Remarks:

/s/ Kevin Gillis by Power of Attorney for Robert I. Tepper, MD

09/12/2014

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

 * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.